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Background: This study aimed to provide an updated analysis of childhood cancer mortality rates and long-term
trends to 2013 to describe the current level of deaths and identify changes in recent decades.
Methods: Data on number of deaths from cancer in children aged under 15 years were derived from Vital Statistics
in Japan and the World Health Organization (WHO) mortality database for comparison countries. Trends in mortality
were examined by fitting a joinpoint regression model.
Results: For all cancers combined, the mortality rate during 2010–2013 was 19.9 per 1,000,000 population for boys
and 17.5 for girls in Japan. Mortality from all cancers combined decreased significantly from 1980 to 2003 for boys
and from 1980 to 2001 for girls. Afterwards, the rates remained stable for both sexes. Mortality from leukemia
declined over the entire study period by 4.6 % per year (p <0.05) in boys and 4.3 % per year (p <0.05) in girls. For
central nervous system (CNS) tumors, a slight increase in mortality was observed for both sexes, with a statistically
significant annual percent change (APC) of 0.5 % (p <0.05) for boys and 0.6 % (p <0.05) for girls.
Conclusions: We provided updated information on recent trends of childhood cancer death. The establishment of
a nationwide, childhood cancer registry is required in Japan. Moreover, trends in cancer mortality should be
monitored continuously.
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Compared with cancers that occur in adults, childhood
cancers are rare, comprising only 0.2 % of all cancers in
Japan in recent years [1]. However, cancer is the common-
est cause of death among Japanese children aged 1–14
years, accounting for 17 % of deaths, according to the Vital
Statistics of 2013 [2]. About 2,300 children under 20 years
of age were diagnosed with cancer in 2011, according to a
recent report from the Medical Aid Program for Chronic
Pediatric Diseases of Specified Categories, a research pro-
ject conducted by the Ministry of Health, Labor and
Welfare, Japan [3].
Although the above Medical Aid Program reports the
number of new cancer patients, data quality is a problem
[4]. The Japan Society of Pediatric Hematology/Oncol-
ogy has also made great efforts to collect data on the* Correspondence: yo-r@ncchd.go.jp
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unless otherwise stated.incidence of childhood cancer, but its registry includes
only some new patients [4]. In fact, Japan has no nation-
wide, childhood cancer registry and thus no accurate esti-
mates of cancer incidence in Japanese children. Therefore,
evaluation of childhood cancer mortality trends is espe-
cially important.
Following our previous report on childhood cancer
mortality in Japan between 1970 and 2006 [5], this art-
icle provides an updated analysis of mortality rates and
long-term trends up to 2013.
Methods
Data on all deaths in Japan from cancer by sex at ages
0–4, 5–9 and 10–14 years during 1980–2013 were ob-
tained from Vital Statistics compiled by the Japanese
Ministry of Health, Labour and Welfare [2]. Death regis-
tration is required by “Family Registration Law” in Japan
[2]. The registration of vital events was believed to be
complete [6, 7]. Population data by sex and age were
available from a Japan national population census, which
is conducted almost every 5 years, and from intercensal
estimates. We calculated age-standardized mortality
rates by the direct method using age-specific mortalityentral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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age distribution of the standard world population (WHO
2000–2025) [8]. We also calculated average age-adjusted
rates, which included age-adjusted rates for six 5-year
periods from 1980–1984 through 2005–2009 and the 4-
year period of 2010–2013.
We analyzed the following malignant tumors: all cancers
combined (International Classification of Diseases (ICD)-
9: 140–208; ICD-10: C00–97), leukemia (ICD-9: 204–208;
ICD10: C91–C95), lymphomas (ICD-9: 200–202; ICD-10:
C81–85, C96), central nervous system (CNS) tumors
(ICD-9: 191–192; ICD–10: C70–C72), malignant kidney
tumors (ICD-9: 189; ICD-10: C64–C66, C68), and malig-
nant bone tumors (ICD-9: 170; ICD-10: C40–C41).
Trends in mortality were examined by fitting a joinpoint
regression model [9]. A maximum of four joinpoints were
allowed, and a minimum of six observations were required
between two joinpoints (including any joinpoint that falls
on an observation) . Permutation tests were used to select
the number of joinpoints. We calculated the average an-
nual percent change (AAPC) from 2000 to 2010 and dur-
ing the last five observations.
For comparison with other countries, we analyzed
1980–2010 mortality data for the United States (US), the
United Kingdom (UK), Italy, and France. Data on deaths
and population were obtained from the World Health
Organization (WHO) mortality database [10]. Because
death is rare from childhood cancer, we avoided coun-
tries with small populations for the comparison. We se-
lected the above four countries because their data in the
WHO mortality database are thought to be complete
[11]. We calculated average age-adjusted mortality rates,
which included five 5-year periods from 1980–1984
through 2000–2004 and a 6-year period of 2005–2010 for
these countries. Mortality rates for each year were calcu-
lated and joinpoint models were fitted for 1980–2010.
Databases used in this study are publicly available.
Age-adjusted mortality rates were calculated using R
version 3.1.0 (Institute for Statistics and Mathematics,
Vienna, Austria; www.R-project.org) [12]. The joinpoint
regression models were fitted using the Joinpoint software,
version 4.0.0, from the Surveillance Research Program of
the US National Cancer Institute (available at http://
srab.cancer.gov/joinpoint) [13]. All calculated p values
are two-sided, and all tests were conducted at a p = 0.05
level of statistical significance.
Results
A total of 20,924 childhood cancer deaths occurred in
Japan during 1980–2013. Three hundred Japanese chil-
dren died from cancer in 2013, of which leukemias were
the most common diagnoses (33.7 %), followed by CNS
tumors (29.3 %). Age-adjusted mortality rates are shown
in Fig. 1. For all cancers combined, the mortality rateduring 2010–2013 was 19.9 for boys and 17.5 for girls,
per 1,000,000 population in Japan. Fig. 2 shows mortality
rates of each year and trends after 1980 for all cancers
combined and other site-based categories in Japan. The
annual percent change for each joinpoint segment and
AAPC are shown in Tables 1 and 2. For Japanese boys,
mortality of all cancers combined decreased significantly
(APC = −3.8, p <0.05) from 54.9 to 20.0 per 1,000,000
population from 1980 to 2003, followed by modest fluc-
tuations after 2003 with a non-significant APC of −1.2 %.
For Japanese girls, a similar mortality decline occurred
from 1980 through 2001 (APC = −3.6, p <0.05), after which
the rate was stable with a non-significant APC of–1.0 %.
Compared with other countries, Japan showed the
lowest mortality in all cancers combined for both sexes
after 2000. Mortality from all childhood cancer declined
during 2000–2010 with AAPCs between–2 % and–3 %
in boys. For girls, declines were observed in all countries
with AAPCs during 2000–2010 between–1 % and–3 %,
although the changes in the UK and Italy were not sta-
tistically significant.
Rates for leukemia in Japan fell significantly over the
whole study period with an APC of–4.6 % (p <0.05) in
boys and–4.3 % in girls (p <0.05). Mortality from
leukemia in the other countries showed a similar decline
with AAPC between–2 % and–5 % for both boys and
girls during 2000–2010.
Deaths from lymphomas among Japanese boys de-
clined significantly during 1986–1998 (APC = −9.8) and
1998–2013 (APC = −3.9). For girls, mortality fell during
1985 to 2013 after a non-significant change between
1980 and 1985. The average annual change in 2000–2010
was–3.9 % (p <0.05) for boys and–7.3 % (p <0.05) for girls.
Significant declines were also observed in the other coun-
tries after 2000.
The mortality rate for CNS tumors remained low in
Japan during the whole period studied. In contrast with
the dramatic decline in deaths from leukemia, mortality
from CNS tumors increased from 1980 to 2013 by 0.5 %
per year (p <0.05) for boys and 0.6 % per year (p <0.05)
for girls. Declines were observed in the US, UK, and
Italy, while in France the APC increased 1.2 % (p <0.05)
for boys and 1.6 % (p <0.05) for girls since 1980.
Deaths from malignant kidney tumors and malignant
bone tumors were rare in Japan, with mortality rates
below two per 1,000,000 population for both sexes. Rates
of kidney cancer declined in the study period by 3.5 %
per year (p <0.05) for boys and 2.9 % per year (p <0.05)
for girls. Declines were also found for malignant bone
tumors, with APC of–1.6 % (p <0.05) for boys and–1.8 %
(p <0.05) for girls. Similar declines occurred in Italy for
both sexes. In the other three countries, mortality from
malignant bone tumors fell in boys during the study
period but remained stable in girls after 2000.
Fig. 1 Childhood cancer mortality rate (per 1,000,000 population) in Japan and other selected countries (solid line, boys; dotted line, girls)
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This updated analysis provides the latest information on
trends in mortality from childhood cancer in Japan. We
found that dramatic declines in mortality occurred dur-
ing 1980–2003 for boys and 1980–2001 for girls. In thelast 5 years, there have been modest but statistically in-
significant reductions in mortality for both sexes.
The declines in childhood cancer mortality in the
1980s and 1990s are most likely due to improved sur-
vival. Early diagnosis and better therapies for childhood
Fig. 2 Age-standardized mortality rates and trends for childhood cancer per 1,000,000 population, Japan, 1980–2013 (solid line, joinpoint fitted
trends for boys; dotted line, joinpoint fitted trends for girls; dots, observed rates)
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prognosis of pediatric cancer patients [14]. The 5-year sur-
vival rate reached 79 % for children with cancer diagnosed
between 1998 and 2000, based on a population-based re-
port from Hiroshima, Japan [15]. The contribution of
changes in cancer incidence to mortality decline remains
unclear because of the absence of incidence data in Japan.
A population-based study in Osaka, Japan that found a de-
cline in the incidence rate of all cancers combined in the1990s suggested that the constant decline in death from
childhood cancer during 1973–2001 was primarily due to
improved survival between the 1970s and 1980s and re-
duced incidence after the 1990s [16].
The impressive decrease in leukemia mortality is consist-
ent with a substantial increase in survival from this disease,
particularly in patients with acute lymphoblastic leukemia.
Standardization of the applied protocol and the expanded
use of chemotherapeutic agents and combination regimens
Table 1 The APC and AAPC of childhood cancer mortality rates in boys
Country Trend 1 Trend 2 Trend 3 Trend 4 AAPC
Years APC Years APC Years APC Years APC 2000-2010 Last 5 Obs
Total malignant tumors
Japan 1980-2003 −3.8* 2003-2013 −1.2 −2.0* −1.2
USA 1980-1985 −4.1* 1985-1998 −3.0* 1998-2003 −0.2 2003-2010 −2.8* −2.0* −2.8*
United Kingdom 1980-2010 −2.4* −2.4* −2.4*
Italy 1980-1989 −4.8* 1989-1994 3.2 1994-1999 −7.5* 1999-2010 −2.0* −2.0* −2.0*
France 1980-1988 −5.1* 1988-2010 −3.0* −3.0* −3.0*
Leukemia
Japan 1980-2013 −4.6* −4.6* −4.6*
USA 1980-2010 −3.6* −3.6* −3.6*
United Kingdom 1980-2010 −3.9* −3.9* −3.9*
Italy 1980-2010 −3.8* −3.8* −3.8*
France 1980-2010 −5.3* −5.3* −5.3*
Lymphomas
Japan 1980-1986 −1.2 1986-1998 −9.8* 1998-2013 −3.9* −3.9* −3.9*
USA 1980-2010 −5.4* −5.4* −5.4*
United Kingdom 1980-2010 −3.4* −3.4* −3.4*
Italy 1980-2010 −3.7* −3.7* −3.7*
France 1980-2010 −5.8* −5.8* −5.8*
Central nervous system tumors
Japan 1980-2013 0.5* 0.5* 0.5*
USA 1980-2010 −1.1* −1.1* −1.1*
United Kingdom 1980-2010 −1.0* −1.0* −1.0*
Italy 1980-2010 −2.1* −2.1* −2.1*
France 1980-2010 1.2* 1.2* 1.2*
Malignant kidney tumors
Japan 1980-2013 −3.5* −3.5* −3.5*
USA 1980-2010 −2.5* −2.5* −2.5*
United Kingdom 1980-2010 −2.4* −2.4* −2.4*
Italy 1980-2010 −3.8* −3.8* −3.8*
France 1980-2010 −3.9* −3.9* −3.9*
Malignant bone tumors
Japan 1980-2013 −1.6* −1.6* −1.6*
USA 1980-2010 −1.4* −1.4* −1.4*
United Kingdom 1980-2010 −2.3* −2.3* −2.3*
Italy 1980-2010 −2.5* −2.5* −2.5*
France 1980-2010 −2.3* −2.3* −2.3*
*p <0.05
APC = annual percent change; AAPC = average annual percent change; Obs = observations
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[17–19]. In the latest report on pediatric hematological
malignancies from the Japan Society of Pediatric
Hematology/Oncology, the 5-year overall survival rate
for patients diagnosed between 2006 and 2010 reached88.7 % for acute lymphoblastic leukemia and 75.2 % for
acute myeloid leukemia [4].
Malignant CNS tumors continue to be the second lar-
gest contributor to cancer-related mortality in Japanese
children. We found a slight but statistically significant
Table 2 The APC and AAPC of childhood cancer mortality rates in girls
Country Trend 1 Trend 2 Trend 3 Trend 4 AAPC
Years APC Years APC Years APC Years APC 2000-2010 Last 5 Obs.
Total malignant tumors
Japan 1980-2001 −3.6* 2001-2013 −1.0 −1.3* −1.0
USA 1980-1995 −2.9* 1995-2010 −1.0* −1.0* −1.0*
United Kingdom 1980-1998 −3.2* 1998-2010 −1.0 −1.0 −1.0
Italy 1980-1989 −4.6* 1989-1994 1.4 1994-2003 −5.8* 2003-2010 1.6 −0.7 1.6
France 1980-2010 −3.0* −3.0* −3.0*
Leukemia
Japan 1980-2013 −4.3* −4.3* −4.3*
USA 1980-1998 −3.5* 1998-2010 −1.7* −1.7* −1.7*
United Kingdom 1980-2010 −3.7* −3.7* −3.7*
Italy 1980-2010 −3.7* −3.7* −3.7*
France 1980-2010 −5.0* −5.0* −5.0*
Lymphomas
Japan 1980-1985 5.2 1985-2013 −7.3* −7.3* −7.3*
USA 1980-2010 −4.5* −4.5* −4.5*
United Kingdom 1980-1985 −18.9* 1985-2010 −2.4* −2.4* −2.4*
Italy 1980-2010 −2.6* −2.6* −2.6*
France 1980-2010 −4.7* −4.7* −4.7*
Central nervous system tumors
Japan 1980-2013 0.6* 0.6* 0.6*
USA 1980-2010 −0.9* −0.9* −0.9*
United Kingdom 1980-2010 −1.1* −1.1* −1.1*
Italy 1980-2010 −2.3* −2.3* −2.3*
France 1980-2010 1.6* 1.6* 1.6*
Malignant kidney tumors
Japan 1980-2013 −2.9* −2.9* −2.9*
USA 1980-2010 −2.2* −2.2* −2.2*
United Kingdom 1980-2010 −1.8* −1.8* −1.8*
Italy 1980-2010 −4.0* −4.0* −4.0*
France 1980-2010 −4.8* −4.8* −4.8*
Malignant bone tumors
Japan 1980-2013 −1.8* −1.8* −1.8*
USA 1980-1988 −5.3* 1988-2010 −0.1 −0.1 −0.1
United Kingdom 1980-1995 −5.4* 1995-2010 2.7 2.7 2.7
Italy 1980-2010 −2.0* −2.0* −2.0*
France 1980-2010 −1.1 −1.1 −1.1
*p <0.05
APC = annual percent change; AAPC = average annual percent change; Obs = observations
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This increase in mortality implies a modest increase in
incidence of CNS tumors. A recent study of mortality of
CNS tumors by subtype between 1993 and 2013 indi-
cates that mortality rises for the tumors of C71.7 (brain
stem) and C71.5 (cerebral ventricle). Since patients withtumors in these sites have a poor prognosis, the trends of
cancer incidence and mortality for these sites are thought
to be similar. Therefore, the study author speculates that
tumors occurring in these sites are increasing [20]. Al-
though this explanation is reasonable, since childhood
CNS tumors are rare and even rarer by subtype, whether
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tumors in Japan awaits confirmation. More importantly,
our results highlight the necessity of establishing an active,
nationwide, childhood cancer registry to provide reliable
incidence information for Japan.
The lack of decline in the mortality rate of CNS tumors
in recent years has also been reported in other countries.
For example, a population-based study in Australia found
a stable trend in mortality between 1998 and 2008. The
author attributed this finding to fluctuations in CNS can-
cer incidence and stable survival rates [21].
Stable trends were observed in mortality of all cancers
combined in recent years in Japan. Accompanying the
rapid reduction in the number of deaths due to leukemia,
the proportion of deaths from CNS tumors increased over
the studied period. In 1980, leukemia accounted for nearly
52 % of childhood cancer deaths; by 2013, it accounted for
34 %. In contrast, CNS tumors’ share of all cancer deaths
increased from about 9 % in 1980 to 29 % in 2013. With
this recent shift in disease distribution, the number of
deaths from leukemia has become similar to that from
CNS tumors in Japan. This means that trends in mortality
of CNS tumors tend to contribute more to the changes in
mortality of all cancers combined. The recent statistically
insignificant drop in mortality from all cancers combined
is due in part to the rise in death from CNS tumors during
the study period.
Our estimates of childhood cancer rates and trends for
Japan are similar to those of four comparison countries,
but some differences exist. For example, mortality from
CNS tumors was lower in Japan than elsewhere. That
difference might be explained by the relatively low dis-
ease incidence rate in Japan since treatment achieve-
ments from using the same regimens are similar in
Japan and other developed countries. Study of the Osaka
Cancer Registry showed an incidence of CNS tumors in
children of about two per 100,000 population between
1988 and 2001 [16]. Even lower rates resulted from a
study of childhood cancer incidence from 1993 to 2001
based on 15 population-based cancer registries in Japan:
1.5 per 100,000 population for boys and 1.4 for girls
[22]. In the same period, a study from the Surveillance,
Epidemiology, and End Results Program reported a
higher childhood cancer incidence rate in the US, over
three per 100,000 population [23].
Data consistency and accuracy should be considered
when comparing Japan with other countries. Our study
used the WHO mortality database, an established, inter-
national death file, to evaluate cancer trends. According
to Mathers et al., for developed countries the quality of
cause-of-death information is good and the coverage of
populations is complete [11]. Hence, we consider our
comparison between Japan and the other four countries
in this study to be reasonable and reliable.The statistical methods used to evaluate changes in
mortality rates may have influenced the observed pat-
terns. In this study, we described trend characteristics
using joinpoint analysis, a method used extensively to
describe mortality trends in epidemiological cancer stud-
ies. Joinpoint analysis allows identification of points of
change and determination of the trends between join-
points, considering variations within the relevant period.
In addition, we calculated both APC and AAPC, which
may provide complete characterization of the trend for
the whole study period.
It is important to address the limitations when explain-
ing and comparing results involving mortality statistics.
First, as described above, the quality of data differs among
countries in the WHO mortality database, and thus com-
parison is limited to those countries with good complete-
ness and accuracy of death certification. Second, the rarity
of childhood cancer deaths limits the analysis of changes
in cancer mortality by subtype. Finally, no known study
has measured the accuracy of cancer death certificate
diagnoses for children with cancer. Although a study of all
age groups reported 65 % agreement of cancer diagnoses
between death certificates and hospital records, whether
this is also true for pediatric cancer is unknown [24, 25].
Conclusions
We provide an update on the recent trends of mortality
of childhood cancer. The dramatic declines in the death
rates of many childhood cancers, especially leukemia,
represent treatment-related improvements in survival.
Establishment of a nationwide, childhood cancer registry
is required in Japan to improve surveillance of incidence
and survival rates. Moreover, trends in cancer mortality
should be monitored continuously.
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